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ARTICLE
Integrative genomic profiling of large-cell
neuroendocrine carcinomas reveals distinct
subtypes of high-grade neuroendocrine lung
tumors
Julie George et al.#
Pulmonary large-cell neuroendocrine carcinomas (LCNECs) have similarities with other lung
cancers, but their precise relationship has remained unclear. Here we perform a compre-
hensive genomic (n= 60) and transcriptomic (n= 69) analysis of 75 LCNECs and identify
two molecular subgroups: “type I LCNECs” with bi-allelic TP53 and STK11/KEAP1 alterations
(37%), and “type II LCNECs” enriched for bi-allelic inactivation of TP53 and RB1 (42%).
Despite sharing genomic alterations with adenocarcinomas and squamous cell carcinomas,
no transcriptional relationship was found; instead LCNECs form distinct transcriptional
subgroups with closest similarity to SCLC. While type I LCNECs and SCLCs exhibit a neu-
roendocrine profile with ASCL1high/DLL3high/NOTCHlow, type II LCNECs bear TP53 and RB1
alterations and differ from most SCLC tumors with reduced neuroendocrine markers, a
pattern of ASCL1low/DLL3low/NOTCHhigh, and an upregulation of immune-related pathways.
In conclusion, LCNECs comprise two molecularly defined subgroups, and distinguishing them
from SCLC may allow stratified targeted treatment of high-grade neuroendocrine lung
tumors.
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Molecular characterization studies have provided invalu-able insight into the relationship between the majorlung tumor subtypes1–7. These studies showed that
morphologically defined lung adenocarcinomas, squamous cell
carcinomas, and small cell carcinomas have distinct molecular
phenotypes based upon their somatically altered genes7. Fur-
thermore, global transcriptional analyses have revealed intra-
group consistency, as well as substantial differences in the pat-
terns of expressed genes, which led to the discovery of novel
intra-group subtypes2,3,8–11 and to the elimination of previous
lung tumor categories (e.g., large-cell carcinoma)7. Of the
remaining lung cancer subtypes, only large-cell neuroendocrine
carcinomas (LCNECs) have so far not been characterized in
depth using both transcriptomic, as well as genomic approaches.
LCNECs account for 2–3% of all resected lung cancers and
belong to the category of neuroendocrine lung tumors, which also
includes pulmonary carcinoids (PCa) and small cell lung cancer
(SCLC)12,13. Contrary to pulmonary carcinoids, LCNEC and SCLC
are clinically aggressive tumors presenting in elderly heavy-
smokers with 5-year survival rates below 15–25% (LCNEC) and
5% (SCLC), respectively12,13. While therapy for both typical and
atypical carcinoids and SCLC is primarily surgery and che-
motherapy (in the case of SCLC), chemotherapy has limited effi-
cacy in LCNEC patients and no standard treatment regimen exists
for this tumor type14. Thus, LCNECs share both commonalities
(e.g., neuroendocrine differentiation) and discrepancies (e.g., lim-
ited response to chemotherapy) with SCLC; however, the under-
lying molecular basis of these shared and distinct features is only
poorly understood. Further complicating the histological classifi-
cation, LCNECs are sometimes found combined with adenocarci-
noma or squamous cell carcinoma and some SCLCs are combined
with a component of LCNEC12,13. Thus, defining the molecular
patterns of this tumor type presents the opportunity to not only
reveal possible novel therapeutic targets, but also help clarifying the
ontogeny and relationship of lung tumors in general.
Previous efforts in characterizing LCNECs through targeted
sequencing of selected cancer-related genes15–17 and through gene
expression profiling18 provided some first insights; however, global
genomic studies combined with transcriptomic analyses have so far
been lacking. Furthermore, given the lack of adequate therapeutic
strategies in LCNECs, a precise delineation of the molecular
boundaries between different neuroendocrine tumors is needed.
We therefore aimed to comprehensively dissect both the muta-
tional and the transcriptional patterns of this tumor type.
In this report, we show that LCNECs are composed of two
mutually exclusive subgroups, which we categorize as “type I
LCNECs” (with STK11/KEAP1 alterations) and “type II LCNECs”
(with RB1 alterations). Despite sharing genomic alterations with
lung adenocarcinomas and squamous cell carcinomas, type I
LCNECs exhibit a neuroendocrine profile with closest similarity
to SCLC tumors. While type II LCNECs reveal genetic resem-
blance to SCLC, these tumors are markedly different from SCLC
with reduced levels of neuroendocrine markers and high activity
of the NOTCH pathway. Conclusively, LCNECs represent a dis-
tinct subgroup within the spectrum of high-grade neuroendocrine
tumors of the lung, and our findings emphasize the importance of
distinguishing LCNECs from other lung cancers subtypes.
Results
Genomic alterations in LCNECs. We collected 75 fresh-frozen
tumor specimens from patients diagnosed with LCNEC under
institutional review board approval (Supplementary Data 1). All
tumors were thoroughly analyzed, and the histological features of
pulmonary LCNECs were confirmed by expert pathologists (E.B.,
W.T., R.B.) according to the 2015 WHO classification13
(Supplementary Data 2). Most tumors were obtained from cur-
rent or former heavy smokers, and enriched for stages I and II
(68%). Nineteen of 75 LCNECs included in this study showed
additional histological components of lung adenocarcinoma
(ADC) (n= 2), squamous cell carcinoma (SqCC) (n= 5) or
SCLC (n= 12) (Supplementary Data 1–2). In subsequent analyses
nucleic acids were extracted only from pure LCNEC regions
(Methods section).
Early genomic profiling studies employing targeted sequencing
of selected cancer-related genes aided in the identification of
some prevalent mutations in LCNECs15–17. In order to assess
globally all genomic alterations in LCNECs and to compare them
to those occurring in other lung tumors, we conducted whole-
exome sequencing (WES) of 55 LCNEC tumor-normal pairs; we
additionally performed whole-genome sequencing (WGS) in
those cases where sufficient material was available (n= 11), thus
amounting to sequencing data of 60 LCNECs in total (six tumors
were both, genome- and exome-sequenced, Supplementary
Fig. 1a). We furthermore performed Affymetrix 6.0 SNP array
analyses of 60 and transcriptome sequencing of 69 tumors
(Supplementary Data 1; Supplementary Fig. 1a). Despite initial
review to include cases with a microscopic tumor content of
>70%, sequencing data analysis revealed a median tumor purity
of 59.5% and a median ploidy of 2.8 (Supplementary Data 1,
Supplementary Fig. 1b, Methods section). On average, LCNECs
exhibited an exonic mutation rate of 8.6 non-synonymous
mutations per million base pairs and a C:G > A:T transversion
rate of 38.7% (Fig. 1a, Supplementary Data 1), indicative of
tobacco exposure1–6. We analyzed the signatures of mutational
processes19,20 in LCNECs, which confirmed a prominent
smoking-related signature (signature 419,20) that accounts for
the majority of all somatic mutations, and which is in general
comparable to most other lung tumors of heavy smokers
(Supplementary Fig. 1c–f, Supplementary Data 3).
Analyses of chromosomal gene copy numbers revealed
statistically significant amplifications of 1p34 (containing the
MYCL1 gene, 12%), 8p12 (containing FGFR1, 7%), 8q24.21
(containing MYC, 5%), 13q33 (containing IRS2, 3%), and 14q13
(containing NKX2-1, also known as TTF-1, 10%) (Q < 0.01,
Supplementary Fig. 2a; Supplementary Data 4–5, Methods
section). Statistically significant deletions affected CDKN2A
(9p21, 8%) and a putative fragile site at PTPRD (9p24, 7%)21.
While amplifications of NKX2-1 and FGFR1 frequently occur in
lung adenocarcinomas1,2,7,21 and squamous cell carcino-
mas3,7,21,22, respectively, MYCL1 amplifications are commonly
found in SCLC4–6,23. Thus, LCNECs harbor significant copy-
number alterations that occur in different lung cancer subtypes.
We next applied analytical filters to identify mutations with
biological relevance in the context of a high-mutation rate and
found eight significantly mutated genes (Q < 0.01, Methods section,
Fig. 1a, Supplementary Data 6–7). TP53 was the most frequently
mutated gene (92%), followed by inactivating somatic events in
RB1 (42%); bi-allelic alterations in both genes, TP53 and RB1—a
hallmark of SCLC4–6—were found in 40% of the cases (Supple-
mentary Fig. 2b, Supplementary Data 6–9). Notably, LCNECs with
admixtures of other histological components mostly had RB1
alterations (Fig. 1a). While genomic alterations in RB1 resulted in
loss-of-nuclear Rb1 expression (P < 0.0001, Fisher’s exact test,
Supplementary Fig. 3a), immunohistochemistry revealed that
absence of Rb1 was not only confined to the LCNEC component,
but also evident in the combined other histological subtype (6/7
cases, Supplementary Fig. 3b, Supplementary Data 2). This may
implicate shared genetic features between LCNECs and the
admixtures of other histological carcinoma types.
We furthermore identified—frequently deleterious—somatic
alterations in functionally relevant domains of STK11 (30%) and
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KEAP1 (22%)1–3 (Fig. 1a, Supplementary Fig. 4a, Supplementary
Data 6–9). Combined with loss-of-heterozygosity (LOH), bi-
allelic alterations of STK11 and KEAP1 were found in 37% of the
cases (Supplementary Fig. 2b, Supplementary Data 8). In those
cases where WGS was performed, we were able to identify larger
genomic rearrangements, which led to the inactivation of RB1,
STK11, or KEAP1 (Fig. 1a, Supplementary Fig. 4a, Supplementary
Data 9). Altogether, somatic alterations of RB1 and STK11/
KEAP1 were detected in 82% of the cases (n= 49) and occurred
in a mutually exclusive fashion (P < 0.0001, Fisher’s exact test,
Fig. 1a). We furthermore observed a trend toward inferior
outcome in patients with RB1-mutated tumors (P= 0.126, log-
rank test, Supplementary Fig. 4b). The genomic profiling thus
points to two distinct subgroups of LCNECs.
We additionally identified statistically significant mutations in
the metalloproteinases ADAMTS2 (15%) and ADAMTS12 (20%),
TP53*#
RB1*#
STK11*#
KEAP1*
KRAS/NRAS/HRAS
NFE2L2
BRAF
ADAMTS12*
ADAMTS2*
GAS7*
NTM*
NKX2-1
MYCL1
PTPRD
CDKN2A
MYC
FGFR1
IRS2
Missense
Non-sense
Indel
Splice
Amplification
Deletion
Histology
M
ut
at
io
ns
pe
r M
b
LCNEC
SCLC combined LCNEC
LCNEC combined SqCC
LCNEC combined ADC
1
10
a
b
100
Genomic translocation
Frequency (%)
0
50
100
A:T->C:G
A:T->T:A
C:G->G:C
C:G->A:T
A:T->G:C
G:C->A:T
R
el
at
iv
e
fre
qu
en
cy
0 20 40 80 90100
0.0
0.2
0.4
0.6
0.8
1.0
n = 16
0.0
0.2
0.4
0.6
0.8
1.0
n = 11
0.0
0.2
0.4
0.6
0.8
1.0
n = 17
0.0
0.2
0.4
0.6
0.8
1.0
n = 4
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
Ca
nc
er
 c
el
l f
ra
ct
io
n 
(C
CF
)
o
f s
om
at
ic 
m
ut
at
io
ns
Clonal
Subclonal
RB1 STK11 KEAP1 RAS genes BRAF NFE2L2
n = 2 n = 3
Mutation of interest
Fig. 1 Genomic alterations in pulmonary large-cell neuroendocrine carcinomas (LCNECs). a Tumor samples are arranged from left to right. Histological
assignments and somatic alterations in candidate genes are annotated for each sample according to the color panel below the image. The somatic mutation
frequencies for each candidate gene are plotted on the right panel. Mutation rates and the type of base-pair substitutions are displayed in the top and
bottom panel, respectively; a dashed black line indicates the average value. Significantly mutated genes and genes with a significant enrichment of
damaging mutations are denoted with * and #, respectively (Q < 0.01, Methods section). Genes with significant copy number (CN) amplifications (CN > 4)
and deletions (CN < 1) (Supplementary Fig. 2a, Supplementary Dataset 5) are displayed in red and blue, respectively (Q < 0.01, Methods section). b The
distribution of clonal and sub-clonal mutations was analyzed for tumor samples that harbored mutations in key candidate genes. The cancer cell fractions
(CCF) of all mutations were determined, assigned to clonal or sub-clonal fractions (Methods section), and displayed as whiskers box-plot (median and
interquartile range, whiskers: 5–95 percentile). The CCF of candidate gene mutations is highlighted in red
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Fig. 2 Gene expression studies on lung cancer subtypes. a A schematic description of the unsupervised consensus clustering approach is provided on the
left panel. The clustering results are displayed on the right panel as a heatmap, in which tumor samples are arranged in columns, grouped according to their
expression clustering class, annotated for the histological subtype and for the somatic alteration status. Expression values of genes identified by ClaNC
(Methods section) are represented as a heatmap; red and blue indicate high and low expression, respectively. Selected candidate genes are shown on the
right. b Significant enrichment of differentially expressed genes in signaling pathways is displayed for all clustering classes (P < 0.0001, Methods section). c
Expression values for key neuroendocrine differentiation markers are plotted for each clustering class as box-plots (median and interquartile range,
whiskers: min–max values). Dashed black lines indicate the threshold for low expression (Methods section). Q < 0.05 (#), significance determined by SAM
(Supplementary Dataset 12); P < 0.001 (***) Mann–Whitney U-test. d The correlation of each sample to the centroid of its clustering class was calculated
and displayed as box-plot (median and interquartile range, whiskers 5–95 percentile)
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and in GAS7 (12%) and NTM (10%) (Q < 0.01, Methods section,
Fig. 1a, Supplementary Fig. 4c, Supplementary Data 6–7), which
so far have not been reported as significantly mutated in any
other lung cancer subtype. The mutations affected functionally
important protein domains, which may suggest a relevant role in
the tumorigenesis of LCNECs (Supplementary Fig. 3c).
We also analyzed LCNECs for alterations in genes of known
tumor-specific functions (e.g., CREBBP, EP3003,4,6,21,
NOTCH3,6,21, MEN124, ARID1A1–3,21,24) (Supplementary Fig. 2b,
Supplementary Fig. 4d, Supplementary Data 6) and found
oncogenic mutations of RAS family genes (KRAS-G12V, -G12C,
NRAS-D57E, HRAS-G13R), NFE2L2 (2 cases with G31V and 1
case with E79Q) and BRAF (V600E, and G469V). Combined with
focal amplifications, RAS genes were affected in 10% of the
tumors (Fig. 1a; Supplementary Data 5–6). We also identified
several private in-frame fusion events, e.g., involving the kinases
NTRK1 and PTK6, which were, however, not recurrent
(Supplementary Fig. 5, Supplementary Data 10). Thus, LCNECs
harbor alterations of oncogenes which are commonly found in
lung adenocarcinomas, but usually absent in neuroendocrine
tumors like SCLC.
The distinct mutational patterns in LCNECs and the presence
of other histological components may suggest a high level of
intra-tumor heterogeneity. We analyzed the clonal distribution of
somatic alterations and determined the cancer cell fraction (CCF)
of each somatic mutation call (Methods section). Despite the fact
that some LCNECs were found with admixtures of other
histological subtypes (Fig. 1a, Supplementary Data 1–2), our
studies on the LCNEC component of such composite tumors
pointed to little intra-tumor heterogeneity with a median of 7%
sub-clonal mutations per sample (Supplementary Fig. 2b–c,
Supplementary Data 1, Methods section). Furthermore, all
relevant and significant mutations were found to be clonal within
the tumor, thus suggesting these alterations as early events during
tumorigenesis (Fig. 1b, Supplementary Data 6).
In summary, genome sequencing revealed distinct genomic
profiles in LCNECs. While certain alterations (e.g., RB1, MYCL1)
resemble patterns found in SCLC4–6,23, others are typical of lung
adenocarcinoma or squamous cell carcinomas (e.g., STK11,
KEAP1, NKX2-1, RAS, BRAF, and NFE2L2)1–3,7,21. Thus,
LCNECs appear to divide into molecularly defined subsets of
tumors with genomic similarities to other major lung cancer
subtypes.
Transcriptional profiles of LCNECs and other lung cancers.
Our sequencing efforts have revealed genomic alterations in
LCNECs that were previously known as canonical alterations in
either, lung adenocarcinomas, squamous cell carcinomas7,21, or
SCLC4–6. In light of these distinct associations, it remained to be
understood if these genomic correlates might reflect a relation-
ship of LCNECs with these lung tumor subtypes on the level of
gene expression. We therefore analyzed whether the transcrip-
tional patterns in LCNECs are correlated with the expression
profiles of other lung cancers.
We compared the expression data of LCNECs with lung
adenocarcinomas2,3,25–27, squamous cell carcinomas3, SCLC6 and
pulmonary carcinoids24 following extensive normalization of the
transcriptome sequencing data (Fig. 2a, Methods section,
Supplementary Data 11). Unsupervised consensus clustering
yielded five consistent expression clusters, which correlated with
the histological annotation of the tumors (P < 0.0001, Fig. 2a,
Supplementary Fig. 6–7, Supplementary Data 12): pulmonary
carcinoids, squamous cell carcinomas and adenocarcinomas
formed distinct transcriptional classes (classes A, B, and C,
respectively), with few LCNECs falling into these groups.
However, the majority of SCLC and LCNECs clustered in two
transcriptional subgroups (classes D and E) (Fig. 2a); a
phenomenon that had previously been observed in other studies
on high-grade neuroendocrine tumors6,18. While the majority of
SCLC tumors formed consensus cluster E (75% of all SCLC cases
analyzed), a fraction of SCLC tumors shared transcriptional
similarities with LCNECs that predominantly formed cluster D.
Thus, LCNECs appear to be more closely related to SCLCs than
to adenocarcinomas or squamous cell carcinomas.
We next analyzed the transcriptome sequencing data for
differentially expressed genes and their enrichment in biological
pathways (Methods section). In line with previous observa-
tions2,3,9–11,18,28, this analysis showed that both adenocarcinomas
and squamous cell carcinomas exhibited upregulation of path-
ways controlling cell differentiation, adhesion and immune
responses, along with higher expression of ERBB2 and TP63
(Fig. 2b, Supplementary Fig. 8a, Supplementary Data 13–14, Q <
0.05, Methods section). Lung neuroendocrine tumors, on the
contrary, showed significantly higher expression of neuroendo-
crine and endocrine markers, Hu antigens (ELAVL3 and
ELAVL4) and the lineage transcription factor and oncogene
ASCL1, which is in agreement with previous studies on lung
cancer subtypes11–13,18,29 (Q < 0.05, Methods section). Further-
more, particularly high expression of the neuronal and endocrine
lineage transcription factors NEUROD1, NEUROD4, and NEU-
ROG330,31 was found in SCLC and LCNECs of transcriptional
class E (Fig. 2a, c, Supplementary Fig. 8b–e, Supplementary
Data 13, Q < 0.05). While recent studies employing SCLC cell
lines and mouse models indicated discordant expression patterns
for ASCL1 and NEUROD131, our sequencing data of human high-
grade neuroendocrine lung tumors revealed expression of both
neuroendocrine lineage factors in class E (Supplementary Fig. 8f).
Within the spectrum of neuroendocrine lung tumors, pulmon-
ary carcinoids formed a distinct subgroup with functional
enrichment in pathways regulating cellular respiration and
metabolism. LCNECs mostly shared similarities with SCLC,
revealing upregulation of pathways and genes controlling cell
cycle and mitosis (E2F transcription factors and checkpoint
kinases), DNA damage response (RAD51, TOP2A, and BRCA1)
and centrosomal functions (such as BUB1, PLK1, and ASPM);
which, to some extent, were also found in squamous cell
carcinomas (Fig. 2b; Supplementary Fig. 8g–i, Supplementary
Data 13–14), and which is in agreement with previous studies18.
Further supporting a molecular relationship of SCLC and
LCNECs in a fraction of the cases, RB1-mutated LCNECs were
enriched in classes D and E (P < 0.05, Fisher’s exact test).
Although, LCNECs also harbored alterations commonly observed
in adenocarcinomas and squamous cell carcinomas, even
LCNECs with such alterations in KEAP1 or STK11 were primarily
found in transcriptional subclasses shared with SCLC (Fig. 2a,
Supplementary Fig. 7c, Supplementary Data 12). Therefore, this
observation supports the view that despite the similarity in
oncogenic mutations, LCNECs rather constitute their own
biological class; and may not be considered as neuroendocrine
versions of adenocarcinomas or squamous cell carcinomas.
We also quantified the consistency of the expression profiles
for each sample with respect to its clustering group. Again, this
analysis revealed a strong correlation for most LCNECs clustering
with SCLC tumors (classes D and E); on the other hand,
expression profiles of those few LCNEC samples clustering with
lung adenocarcinomas, squamous cell carcinomas, and pulmon-
ary carcinoids were less consistent (Fig. 2d). Furthermore, we
performed separate transcriptional clustering of LCNECs with
adenocarcinomas and squamous cell carcinomas only (excluding
SCLC), which did not suggest any unrecognized similarities
between these lung cancer subtypes (Supplementary Fig. 9). Thus,
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despite sharing somatic alterations with other tumor subtypes,
such as adenocarcinomas and squamous cell carcinomas,
LCNECs were transcriptionally dissimilar with all non-
neuroendocrine lung tumors and showed closest similarities to
SCLC.
The transcriptional relationship of LCNEC and SCLC. In the
previous section, we sought for a global approach to identify
common and distinct transcriptional profiles of LCNECs in
relationship with other lung tumors, which showed that LCNEC
and SCLC appear to share most transcriptional patterns.
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However, strongly divergent tumors (e.g., carcinoids, adeno-
carcinomas) may drive these clusters and mask important dif-
ferences between LCNECs and SCLC. We therefore sought to
directly compare LCNECs and SCLC on the transcriptional level
(Fig. 3a). The resulting unsupervised clustering analysis revealed
four consensus clusters of LCNEC and SCLC that we termed
classes I–IV in order to distinguish them from the above-
mentioned classes A–E (Fig. 3a, Supplementary Fig. 10–11,
Supplementary Data 12). Class I exclusively included LCNECs
with STK11 or KEAP1 alterations; yet, a few cases with these
alterations fell into class II that predominantly consisted of
LCNECs with RB1 loss (Fig. 3a). Some LCNECs, including
tumors admixed with SCLC (“SCLC combined LCNECs”)—
clustered with the majority of SCLC tumors in the classes III and
IV; similarly, some SCLC tumors were part of class II that
included LCNECs bearing RB1 alterations (Fig. 3a, Supplemen-
tary Fig. 11). Even though pathological review had been con-
ducted to distinguish histological subtypes from one another,
transcriptional clustering suggested high degrees of similarity for
some LCNEC and SCLC cases; these tumors may therefore be
considered as “SCLC-like” and “LCNEC-like” (Fig. 3a, Supple-
mentary Fig. 11, Supplementary Data 11). Other major genome
alterations (e.g., NKX2-1, MYCL1, RAS genes, NFE2L2, BRAF)
did not segregate with the identified transcriptional subgroups
(Supplementary Fig. 11). We further analyzed the consistency of
the transcriptional subgroups by clustering LCNECs alone, which
revealed high concordance with the transcriptional classes iden-
tified in Fig. 3a (62/66 cases, 94%, P < 0.001, Fisher’s exact test,
Supplementary Fig. 13, Supplementary Data 12). Thus, despite
the similarities between LCNECs and SCLCs, subtypes of
LCNECs exist with profound differences to SCLC.
The transcriptional clustering heatmap pointed to a strong
gene expression pattern shared by all LCNECs bearing STK11/
KEAP1 alterations (Fig. 3a, Supplementary Fig. 12a, green box in
upper left quadrant). We therefore conducted a supervised
analysis of the gene expression data, in which LCNECs with
STK11/KEAP1 alterations were compared to tumors bearing RB1
alterations. This analysis indicated specific expression profiles,
which were similar to those observed in tumors constituting class
I (Fig. 3b, Supplementary Fig. 12, Supplementary Data 13). We
therefore assigned this genomic subset of tumors to one group,
termed “type I LCNECs”.
Type I LCNECs exhibited high levels of calcitonin A (CALCA),
a known marker of pulmonary neuroendocrine cells32–34 (Fig. 3a,
Supplementary Fig. 12b, Supplementary Data 13). This subgroup
furthermore displayed a pronounced upregulation of cellular
metabolic pathways, which we also observed in pulmonary
carcinoids (Fig. 2b), but which was less prominent in LCNECs
and SCLC tumors with RB1 alterations (Fig. 3a, b, Supplementary
Data 12–13). Other genes found in type I LCNECs included
gastrointestinal transcription factors (e.g., HNF4A, HNF1A, and
RFX6), which were previously reported to play a role in
de-differentiated lung tumors35,36 (Fig. 3b, Supplementary
Fig. 12c, d, Supplementary Data 13).
The most striking difference was found in the expression levels
of neuroendocrine genes: while type I LCNECs and the majority
of SCLC tumors (class III+ IV) harbored high levels of
neuroendocrine genes (CHGA and SYP; Fig. 3c; Supplementary
Fig. 12e; Supplementary Data 12), most LCNECs and some SCLC
tumors with RB1 alterations in class II exhibited low levels of
these genes (Fig. 3c, Supplementary Fig. 12e). By contrast, tumors
in class II displayed elevated expression of genes associated with
active Notch signaling (e.g., NOTCH1, NOTCH2, and HES1) and
immune cell responses (e.g. PDCD1LG2, TLR4, and CTSB)
(Fig. 3a, d, Supplementary Fig. 12f, Supplementary Data 12–13).
Given the strong enrichment of LCNECs with STK11 or KEAP1
alterations in cluster I, and the prominent lack of expression of
key neuroendocrine genes in most tumors of class II, we termed
LCNECs within this transcriptional class as “type II LCNECs”.
We have recently demonstrated that SCLC tumors usually
harbor inactive Notch signaling and that activation of Notch
reduces expression of neuroendocrine genes (e.g., CHGA, SYP and
NCAM1) and Ascl16. Consistent with this notion, we found that
type II LCNECs and some SCLC within this transcriptional class
exhibited signs of NOTCH upregulation and low expression of
neuroendocrine markers, ASCL1 and DLL3, an inhibitor of the
Notch signaling pathway37 (Fig. 3d, and Supplementary Fig. 12f).
Conversely, type I LCNECs and the majority of the SCLC samples
(class III and IV) showed higher levels of neuroendocrine genes, as
well as of ASCL1 and DLL3, and downregulation of NOTCH
pathway genes (Fig. 3d, Supplementary Fig. 12f). Thus, despite the
fact that type II LCNECs and some SCLCs harbor bi-allelic loss of
TP53 and RB1, their transcriptional signatures include low levels of
neuroendocrine genes and a distinct profile of NOTCHhigh and
ASCL1low/DLL3low, which differentiates these tumors from type I
LCNECs and from the majority of SCLC cases. We did not identify
any significant enrichment of somatic alterations in NOTCH
pathway genes, which may explain these transcriptional differences
(Supplementary Fig. 11). However, a recent study in a pre-clinical
mouse model has established a central role of REST as a repressor
of neuroendocrine markers in SCLC38. Compatible with these
findings, type II LCNECs displayed significantly higher levels of
REST (clustering class II, Supplementary Data 12, Q < 0.05), which
may explain the low neuroendocrine phenotype in type II LCNECs
marked by ASCL1low/DLL3low/NOTCHhigh. Given the important
role of NOTCH signaling and ASCL1 in the decision of
neuroendocrine fate and the development of neuroendocrine lung
tumors29,31,38, these findings provide further support for our
distinction of type I and II LCNECs.
We next analyzed the relationship of the expression classes I–IV
using hierarchical clustering, which revealed two major subgroups
(Supplementary Fig. 11): one subgroup mainly consisting of
LCNECs (type I and II LCNECs), and the other subgroup mainly
containing SCLC tumors (classes III and IV). Thus, despite
harboring distinct transcriptional subcategories, LCNEC and SCLC
tumors largely followed their histological annotation and formed
separate transcriptional subgroups. Differentially expressed genes
included SOX1 and the neuroendocrine Hu genes (ELAVL3,
Fig. 3 Gene expression studies on LCNEC and SCLC. a The expression profiles of LCNEC and SCLC tumors were analyzed following the annotation and
approach described in Fig. 2a. Expression values of genes identified by ClaNC (Methods section) are represented as a heatmap in which red and blue
indicate high and low expression, respectively. Selected candidate genes are shown on the right. Dashed green lines indicate an expression profile shared
by LCNEC tumors with STK11/KEAP1 alterations (type I LCNECs). b The significant enrichment of differentially expressed genes and signaling pathways are
displayed for type I LCNECs and type II LCNECs. P < 0.0001 (Methods section); * some SCLC tumors that co-clustered with type II LCNECs were included
in this analysis. Key candidate genes are highlighted in bold. c, d Expression values for c the key neuroendocrine differentiation markers SYP
(synaptophysin) and CHGA (chromogranin A) (scatter plot), and d NOTCH pathways genes (box plots: median and interquartile range, whiskers: min–max
values). e Significant enrichment of differentially expressed genes and signaling pathways was analyzed for class I and II vs class III and IV tumor samples;
P < 0.0001 (Methods section). f Expression values of SOX1, ELAVL3, and ELAVL4 are plotted for the clustering classes and other lung cancer subtypes (box
plots: median and interquartile range, whiskers: min–max values). Q < 0.05 (#), SAM (Supplementary Dataset 12); P < 0.01 (**) Mann–Whitney U-test
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ELAVL4), which were enriched in most SCLC samples (classes III
and IV (Supplementary Data 13, Q < 0.05, Methods section)
(Fig. 3f). This observation is in line with previous reports on auto-
antibodies against Sox1 and Hu-proteins that are commonly found
in SCLC patients39. While pulmonary carcinoids harbored similar
expression levels, these genes were essentially absent or only
moderately expressed in most LCNECs and other lung cancer
subtypes (Fig. 3f).
We furthermore analyzed the impact of transcriptional
subgroups on tumor stage and clinical outcome. While, we found
no association of tumor stage with the molecular subsets found in
high-grade neuroendocrine tumors (Supplementary Data 12), we
observed a trend toward inferior survival in patients with SCLC
(transcriptional profiles of classes III and IV; P= 0.072, log-rank
test, Supplementary Fig. 14), which was similarly observed in
previous studies on high-grade neuroendocrine lung tumors18.
Conclusively, LCNECs exhibit a distinct expression profile
within the spectrum of high-grade neuroendocrine lung tumors,
which can further be divided into two subtypes: type I LCNECs
with high neuroendocrine expression and, similar to SCLC, a
profile of ASCL1high/DLL3high/NOTCHlow, and type II LCNECs
with reduced expression of neuroendocrine genes and a pattern of
ASCL1low/DLL3low/NOTCHhigh (Fig. 4).
Discussion
Here we provide the first comprehensive molecular analysis of
LCNECs, which allowed distinguishing between two genomic
subgroups with specific transcriptional patterns, defined as “type I
LCNECs” and “type II LCNECs” (Fig. 4).
Type I and II LCNECs harbor key genomic alterations and
oncogenic mutations, which are commonly found in SCLC, lung
adenocarcinoma or squamous cell carcinoma (e.g., in RAS genes,
BRAF, NFE2L2, as well as in STK11 and KEAP1 in the case of
type I LCNECS, and RB1 losses in the case of type II LCNECs).
One possible explanation for this observation might be a high
level of intra-tumor heterogeneity, combined with occurrence of
two tumor types in a single tumor. However, the key alterations
that we found in LCNECs were mostly clonal, with limited
genomic intra-tumor heterogeneity. Furthermore, thorough
comparisons of gene expression profiles did not suggest simila-
rities between LCNECs and lung adenocarcinomas or squamous
cell carcinomas. Thus, the combinations of distinct sets of
mutations with specific patterns of gene expression supports the
view that LCNECs are not a variant of the other types of lung
cancer, but represent a distinct subgroup within the spectrum of
neuroendocrine lung tumors.
In a more focused comparison with the most frequent neu-
roendocrine type of lung cancer, SCLC, type I LCNECs with
STK11 and KEAP1 alterations exhibited a high degree of simi-
larity with these carcinomas, as well as high expression of neu-
roendocrine genes and a profile of ASCL1high/DLL3high/
NOTCHlow. By contrast, type II LCNECs with RB1 alterations
revealed reduced expression of neuroendocrine genes and a pat-
tern of ASCL1low/DLL3low/NOTCHhigh. Notch family members
play a multifaceted role in the development of neuroendocrine
tumors with cell-type specific tumor suppressor and oncogenic
functions40. We have shown in earlier studies that NOTCH serves
as a tumor suppressor in SCLC6, which mostly harbor high-level
expression of the negative regulator of Notch, DLL36,37,41 (Fig. 4).
A recent clinical trial with an antibody-drug conjugate targeting
the non-canonical inhibitory NOTCH ligand, Dll3, has shown
early signs of clinical activity in SCLC37,41. We now demonstrate
shared neuroendocrine pathways between SCLC and type I
LCNECs, which may be similarly susceptible to this agent. On the
other hand, type II LCNECs with alterations in RB1 exhibited
active Notch signaling (Fig. 4). Clinical trials have assessed the
efficacy of an antibody targeting Notch 2 and 3 in SCLC, but
recently failed in demonstrating a clinical benefit42,43. Therefore,
future clinical trials involving therapeutics, targeting activating or
inhibitory members of the Notch pathway will—in our view—
require clear assignment of the respective molecular subtype.
Perhaps another noteworthy finding, type II LCNECs exhibited
a pattern of gene expression with upregulation of immune related
pathways (Fig. 3b, Fig. 4), which has similarly been observed in
various other tumor types28 and which may impact the response
of patients to immunotherapy. Taken together, the precise dis-
tinction of high-grade neuroendocrine tumors representing as
type I LCNECs and as RB1-mutated SCLC or type II LCNECs,
may be pivotal to assess the efficacy of targeted therapeutics,
including Notch pathway and immune checkpoint inhibitors.
Our sequencing studies did not reveal any somatic events that
may cause the transcriptional discrepancy observed in LCNEC and
SCLC tumors with TP53 and RB1 alteration, which raises the
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High-grade neuroendocrine lung tumors
TP53mut
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Fig. 4 Schematic overview of somatic alterations and expression profiles in high-grade neuroendocrine lung tumors. Significantly mutated genes are shown
in black and differentially expressed genes are highlighted in red and blue, describing higher and lower expression, respectively. Upregulated expression
profiles and signaling pathways are indicated by color gradients
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question if all neuroendocrine tumors share the same cell of origin.
It remains to be understood whether distinct tumor-specific cell of
origins or cellular processes allow for plasticity and trans-
differentiation that consequently lead to distinct molecular phe-
notypes. Importantly, histological trans-differentiation from lung
adenocarcinoma to SCLC has been observed, both spontaneously
or as resistance mechanisms to kinase inhibitors44,45; in some cases
these were linked with a loss of RB14,46. Previous studies involving
genetically engineered mouse models and human cell lines have
emphasized the phenomenon of transcriptional heterogeneity in
SCLC and pointed to discordant expression of key lineage factors
(e.g. ASCL1, NEUROD1, REST)31,38. By contrast, human primary
tumors revealed a more complex expression pattern with co-
expression of these transcriptional regulators. As a limitation of
bulk tumor sequencing, advances in single cell sequencing may
further aid to resolve and study the level of transcriptional intra-
tumor heterogeneity in high-grade neuroendocrine tumors. While
our studies pointed to transcriptional correlates of genomically
defined subsets in LCNECs (type I and type II LNCECs), additional
analyses on a larger dataset are warranted to further interrogate
subcategories of high-grade neuroendocrine tumors.
In summary, we provide the first comprehensive character-
ization of neuroendocrine lung tumors, which integrates the
molecular phenotypes of less frequent lung tumor subtypes.
Despite the fact that LCNEC and SCLC tumors share some
common clinical and histological characteristics, our study
emphasizes pronounced differences in the pattern of genomic
alterations and in their transcriptome profiles. The precise dis-
tinction of type I and type II LCNECs from SCLC is consequently
pivotal to evaluate the response of patients to treatment options
and to further understand morphological trans-differentiation
processes in lung cancer patients.
Methods
Human specimens. The institutional review board (IRB) of the University of
Cologne approved this study. Patient samples were obtained under IRB-approved
protocols following written informed consent from all human participants. We
collected and analyzed fresh-frozen samples of 75 LCNEC patients, which were
provided by multiple collaborating institutions; 42 tumors were previously subject
of other studies conducted by Rousseaux et al.47 (n= 25) and Seidel et al.7 (n= 37)
(Supplementary Data 1). Clinical data were available for most patients, who were
predominantly male (approximate ratio of 4:1) and current or former heavy
smokers (Supplementary Data 1). All tumor samples were reviewed and confirmed
by independent expert pathologists (E.B., W.T., and R.B.), and the diagnosis of
LCNEC and the assessment of combined histological components were confirmed
by H&E staining and immunohistochemistry, including markers for chromogranin
A, synaptophysin, CD56 and Ki67. All tumors were positive for at least one
neuroendocrine differentiation marker (Supplementary Data 1–2). Specimens
containing >70% of tumor cells were processed for DNA and RNA extractions.
DNA was extracted from matching normal material that was provided in the form
of blood or adjacent non-tumorigenic lung tissue, which through pathological
evaluation was confirmed to be free of tumor contaminants.
Nucleic acid extraction. Total DNA and RNA were obtained from fresh-frozen
tumor tissue and matched fresh-frozen normal tissue or blood. Depending on the
size of the tissue, 15–30 sections, each 20 μm thick, were cut using a cryostat (Leica)
at –20 °C. The matched normal sample obtained from frozen tissue was processed
the same way. Nineteen LCNEC cases were identified with mixed histological
components of SCLC, lung adenocarcinomas and squamous cell carcinomas
(Supplementary Data 1); in these cases nucleic acids were extracted from
pure LCNEC regions by only dissecting the LCNEC component. DNA was
extracted with the Gentra Puregene DNA extraction kit (Qiagen) and diluted to a
working concentration of 100 ng/μL. The DNA was analyzed by agarose gel elec-
trophoresis and confirmed to be of high-molecular weight (>10 kb). The DNA of
tumor and normal material was confirmed to originate from the same patient by
short tandem repeat (STR) analysis which was conducted at the Institute of Legal
Medicine at the University of Cologne (Cologne, Germany), or by subsequent
Affymetrix 6.0 SNP array and sequencing analyses.
RNA was isolated from tumor tissues by first lysing and homogenizing tissue
sections with the Tissue Lyzer (Qiagen). The RNA was then extracted with the
Qiagen RNAeasy Mini Kit. The RNA quality was analyzed at the Bioanalyzer 2100
DNA Chip 7500 (Agilent Technologies) and cases with a RNA integrity number
(RIN) of over seven were considered for RNA-seq experiments.
Next-generation sequencing (NGS). WES was performed by first fragmenting 1 μg
of DNA (Bioruptor, diagenode, Liége, Belgium). The DNA fragments were then end-
repaired and adaptor-ligated with sample index barcodes. Following size selection, the
SeqCap EZ Human Exome Library version 2.0 kit (Roche NimbleGen, Madison, WI,
USA) was used to enrich for the whole exome. The DNA libraries were then
sequenced with a paired-end 2 × 100 bp protocol aiming for an average coverage of
90× and 120× for the normal and tumor DNA, respectively. The primary data were
filtered for signal purity with the Illumina Realtime Analysis software.
WGS was performed with a read length of 2 × 100 bp. The samples were
processed to provide 110 Gb of sequence, thus amounting to a mean coverage of
30× for both tumor and matched normal.
For RNA-seq, cDNA libraries were prepared from PolyA+ RNA following the
Illumina TruSeq protocol for mRNA (Illumina, San Diego, CA, USA). The libraries
were sequenced with a paired-end 2 × 100 bp protocol resulting in 8.5 Gb per
sample, and thus in a 30× mean coverage of the annotated transcriptome.
Whole genome, whole exome and transcriptome sequencing reactions were
performed on an Illumina HiSeq 2000 sequencing instrument (Illumina, San
Diego, CA, USA).
Copy-number analysis by Affymetrix SNP 6.0 arrays. Human DNA from fresh-
frozen tumors was analyzed with Affymetrix Genome-Wide Human SNP 6.0
arrays to determine copy-number alterations. Raw copy number data were com-
puted by dividing tumor-derived signals by the mean signal intensities obtained
from a subset of normal samples which were hybridized to the array in the same
batch. Circular binary segmentation was applied to obtain segmented raw copy
numbers48. Significant copy-number alterations were assessed with CGARS49 at a
threshold of Q < 0.01 (Supplementary Data 4).
Data processing and analyses of DNA sequencing data. The sequencing reads
were aligned to the human reference genome NCBI build 37 (NCBI37/hg19) with
BWA (version 0.6.1-r104)50. Possible PCR-duplicates were masked and not included
for subsequent studies. We applied our in-house analysis pipeline4,6,51 to analyze the
data for somatic mutations, copy number alterations and genomic rearrangements. In
brief, the mutation calling algorithm considers local sequencing depth, forward-
reverse bias, and global sequencing error, to thus determine the presence of a mutated
allele. We determined the somatic status of these mutations by assessing the absence
of these variants in the sequencing data of the matched normal.
We determined genomic rearrangements from WGS data of 11 human
LCNECs following the procedure as previously described6,51. In brief, the
sequencing data were analyzed for discordant read-pairs, which were not within
the expected mapping distance (>600 base pairs) or which revealed an incorrect
orientation. Discordant read-pairs were analyzed for breakpoint-spanning reads, in
which one read-pair shows partial alignments to two distinct genomic loci.
Rearranged genomic loci were then reported at instances where at least one
breakpoint-spanning read was identified. The genomic rearrangements called from
each tumor sample were further filtered against the sequencing data of a matched
normal and additionally against a library of normal genomes to thus minimize the
detection of false-positive rearrangements.
Significantly mutated genes were analyzed as previously described4,6. In brief,
we first determined the overall background mutation rate of each gene by
computing its expected number of mutations assuming that all mutations are
uniformly distributed across the genome. We also considered the ratio of
synonymous to non-synonymous mutations into a combined statistical model to
determine significantly mutated genes. Since mutation rates in non-expressed genes
are often higher than the genome-wide background rate, we furthermore filtered
for the expression of genes by referring to the transcriptome sequencing data of
LCNECs. Only genes with a median FPKM (Fragments Per Kilobase Million) value
of >1 in at least 35 out of 60 samples were considered (Methods section: RNA
sequencing data processing and analyses). The significance of recurrently mutated
genes was determined at a Q-value of <0.01 (Supplementary Data 7). Following
previously described methods, we furthermore analyzed the data for significant
enrichment of damaging mutations (including splice site, non-sense, and
frameshift mutations)6 and for significant clustering of mutations in genomic
hotspots following a re-sampling based approach4. Significance was determined at
a Q-value of 0.01, if the gene was affected in >10% of the samples (Supplementary
Data 7). The damaging impact of mutations was further assessed by Polyphen52.
The clonal status of mutations was assessed by computing for every mutation
the “cancer cell fraction” (CCF), which defines within a tumor the fraction of
cancer cells harboring that particular mutation53. The CCF was computed
following our previously described approach6. In brief, this method first estimates
tumor purity, ploidy, and absolute copy numbers, and computes for each mutation
in a given sample the expected allele frequency under the assumption of clonality.
The CCF is the quotient of the observed allelic fraction and the expected allelic
fraction of a mutation. The distribution of CCFs for every mutation in a sample
allowed to further identify distinct clusters and to thus assign the mutations to
clonal and subclonal populations. The analysis described in Supplementary Fig. 2c
considers mutations, which were assigned to clonal and subclonal fractions with a
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03099-x ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1048 | DOI: 10.1038/s41467-018-03099-x |www.nature.com/naturecommunications 9
probability >90%. In consideration of the sequencing coverage and the overall
distribution of CCFs of every mutation in a sample, we furthermore determined the
significant enrichment of mutations in a subclone at a P-value of 0.01 (Fig. 1b).
Mutational signatures analyses. Mutational signatures were analyzed in lung
cancer subtypes applying previously described methods54,55 and referring to the
datasets of 77 lung adenocarcinomas (50 heavy-smokers (hs) and 27 non-smokers
(ns) from the TCGA project)2,25, 52 lung squamous cell carcinomas (from the
TCGA project)3, 109 SCLC6, and 60 LCNECs from this study. Tumor cases with at
least 30 somatic variants were selected and the list of variants were either extracted
from Supplementary Materials6 or COSMIC v68 (for the TCGA data)20. Variants
were annotated with Annovar (version 12 Nov 2014). Gene strand orientations
were retrieved from the RefSeqGene database using a customized Perl script.
Variants were included in the analyses only if they could be successfully annotated.
Single-base substitutions were classified into 96 types determined by the six pos-
sible substitutions (C:G > A:T, C:G > G:C, C:G > T:A, A:T > C:G, A:T > G:C, A:T >
T:A) in their tri-nucleotides sequence context (16 combinations for each type of
substitution). For extracting mutational signatures, we used the non-negative
matrix factorization (NMF) algorithm developed by Lee et al.56 and implemented
in the Welcome Trust Sanger Institute (WTSI) mutational signatures framework.
Di-deoxynucleotide sequencing. Somatic alterations of interest were determined
and confirmed by two independent sequencing approaches, which included WGS,
WES, RNA-seq or di-deoxynucleotide sequencing. Di-deoxynucleotide chain ter-
mination sequencing (Sanger sequencing) was performed to validate mutations,
genomic rearrangements, and chimeric fusion transcripts. Primer pairs were
designed to amplify the target region encompassing the somatic alteration. The
PCR reactions were performed either with genomic DNA or cDNA. The amplified
products were subjected to Sanger sequencing and the respective electro-
pherograms were analyzed by visual inspection using 4 Peaks or Geneious.
Analysis of RNA sequencing data. In order to detect chimeric transcripts, RNA-
seq data were processed using TRUP4,27. In brief, paired-end RNA-seq reads were
aligned to the human reference genome (NCBI37/hg19). We used TRUP to
identify potential chimeric transcripts. Gene expression levels were determined
with Cufflinks v2.0.2 referring only to paired-end reads that uniquely mapped
within the expected mapping distance. The expression was quantified as FPKM
(Fragments Per Kilobase Million) and the expression values served as a filter for
identifying significantly mutated genes (Methods section: Data processing and
analyses of DNA sequencing data).
Gene expression profiling and clustering studies. We analyzed transcriptome
sequencing data from a total of n= 341 lung cancer samples. N= 221 samples
referred to the data generated at the University of Cologne, Department of
Translational Genomics, which included 41 lung adenocarcinoma26,27, 61 pul-
monary carcinoids24, 53 SCLC6, and 66 LCNECs from this present study. N=
120 samples were randomly selected from both the TCGA lung squamous cell
carcinoma (n= 60)3 and TCGA lung adenocarcinoma (n= 60) cohorts2,25 refer-
ring to the Genomics Data Commons Legacy Archive. Sequencing data of lung
adenocarcinomas from two different platforms aided in controlling for potential
batch effects in subsequent studies. The raw sequencing reads of the RNA-seq data
were all similarly processed to analyze for gene expression profiles. Sequencing
reads which passed the quality control were mapped to the human reference
genome (hg19) using MapSplice57. Picard Tools v1.64 (http://broadinstitute.github.
io/picard/) was used to assess the alignment profile. SAMtools was used to sort and
index the mapped reads and to determine transcriptome coordinates. The aligned
reads were further filtered for indels, large inserts, and zero mapping quality with
UBU v1.0 (https://github.com/mozack/ubu). RSEM58, an expectation-
maximization algorithm that refers to UCSC gene transcript and definitions, was
applied to estimate transcript abundance. In order to allow comparisons between
all RNA-Seq samples, raw RSEM read counts were normalized to the overall upper
quartile59. The expression was quantified for 20,500 genes in 341 tumor samples
and the median expression value was determined at RSEM= 209, which served as
a reference threshold to classify for low and high expression. The expression
determined by RSEM is provided for LCNECs in Supplementary Data 11.
For clustering purposes a set of genes that were both highly expressed and had
highly variable expression patterns was identified in all lung cancer subtypes.
Quality control procedures performed prior to any clustering analysis did not
detect any evidence of batch effects.
After median centering the log2(RSEM+ 1) values by gene, unsupervised
consensus clustering was applied using the ConsensusClusterPlus R package60,61
with partitioning around medioids and a Spearman correlation-based distance.
Additional hierarchical clustering of the consensus clustering classes was
performed, applying average linkage and a Pearson correlation-based distance.
The statistical significance of the differences in gene expression patterns present
in the subtype was assessed with the SigClust R package62 by referring to the
clustering gene sets and by using 1000 permutations and the default covariance
estimation method. ClaNC63 was used to identify genes whose expression patterns
characterize the subtypes. R 3.0.261 was used to perform all statistical analyses and
create all figures.
We first conducted consensus clustering of all lung cancer subtypes. The
expression data of all lung cancer subtypes (n= 341) was analyzed and the 0.75
quantile of all log2(mean(RSEM)) values was used to identify highly expressed
genes, while the 0.9 quantile of log2(variance(RSEM)) was used as a threshold to
identify clustering gene sets that have highly variable expression patterns, which
yielded a set of 1854 genes (Supplementary Fig. 6a). The samples were clustered
with ConsensusClusterPlus following partition around medoids (PAM), and the
ConsensusClusterPlus output along with gene expression heatmaps, principal
components analysis, and silhouette plots was analyzed. Manual review of
ConsensusClusterPlus output suggested a possible clustering solution based on k=
6 groups. However, two of the six groups included mainly lung adenocarcinoma
samples and the gene expression heatmaps and PCA plots showed that these
groups were quite similar. Thus, we chose to collapse these groups, thereby
producing a five-class solution. The consensus clusters highly correlated with the
histological subtypes as determined by Fisher’s exact test Monte Carlo version (P <
0.001, 10,000 permutations): class A (n= 66; enriched for pulmonary carcinoids),
class B (n= 65, enriched for lung squamous cell carcinomas), class C (n= 108,
enriched for lung adenocarcinomas; data generated by different institutes), class D
(n= 38, enriched for LCNEC and SCLC cases), and class E (n= 64, enriched for
SCLC and LCNEC cases) (Supplementary Fig. 6b, Supplementary Data 12). ClaNC
led to the identification of 875 classifier genes, which are displayed in the
expression heatmaps (Fig. 2, Supplementary Fig. 6–7, Supplementary Data 13).
We then conducted consensus clustering of LCNECs, SCLC, lung
adenocarcinomas, and squamous cell carcinomas. The unsupervised clustering
approach was repeated for a subset of lung cancer subtypes; here excluding
pulmonary carcinoids. The feature selection of highly variable (0.75 quantile) and
highly expressed (0.9 quantile) genes across these lung tumor subtypes (n= 280)
involved a gene set of 1855 genes and the consensus clustering process through
hierarchical clustering suggested the presence of three expression clusters
(expression subtypes): class A (n= 98, enriched for lung adenocarcinomas), class B
(n= 115, enriched for LCNEC and SCLC), and class C (n= 67, enriched for lung
squamous cell carcinomas). ClaNC identified 300 classifier genes which are
displayed in the respective expression heatmaps (Supplementary Fig. 9).
We performed consensus clustering of LCNEC and SCLC through
unsupervised clustering of the expression data of LCNEC and SCLC tumors alone
(n= 119). Exploratory analyses of the gene expression data suggested the use of the
0.9 quantile of both the log2(mean(RSEM)) and log2(variance(RSEM)) values as
thresholds for highly expressed and highly variably expressed genes. This produced
a set of 1416 clustering genes. The Consensus clustering approach included
hierarchical clustering and yielded four gene expression subtypes: class I (n= 19,
only LCNECs), class II (n= 49, LCNEC and some SCLC tumors), class III (n= 10,
SCLC and some LCNECs), and class IV (n= 41, mainly SCLC and some LCNECs)
(Fig. 3, Supplementary Fig. 10–11, Supplementary Data 12). Hierarchical clustering
of these cases revealed two main subgroups: one mainly formed by class I and II
(enriched for LCNECs) and one mainly formed by class III and IV (enriched for
SCLC) (Supplementary Fig. 11). 300 classifier genes were identified by ClaNC and
are displayed in the expression heatmaps (Fig. 3, Supplementary Fig. 11,
Supplementary Data 13).
We also performed consensus clustering of LCNECs with lung
adenocarcinomas or lung squamous cell carcinomas. A gene set of (a) 1335 and (b)
1338 highly variable (0.85 quantile) and expressed genes (0.925 quantile) was
identified in subsets of lung cancer tumors, including (a) LCNECs and lung
adenocarcinomas (n= 167) and (b) LCNECs and lung squamous cell carcinomas
(n= 126). The consensus clustering approach through PAM (partitioning around
medoids) suggested in both cases two transcriptional subclasses: for approach (a)
class A (n= 70, mainly LCNECs) and class B (n= 97, mainly lung
adenocarcinomas); and for approach (b) class A (n= 58, mainly LCNECs) and
class B (n= 68, mainly lung squamous cell carcinomas). ClaNC identified 100
classifier genes in each approach, which were used for the expression heatmaps
(Supplementary Fig. 9).
We furthermore performed consensus clustering of LCNECs alone. The
transcriptional data on LCNECs was analyzed and hierarchical clustering referred
to 475 very highly expressed (0.875 quantile) and very highly variable (0.975
quantile) genes. The consensus clustering approach yielded a k= 4 clustering
solution: class 1 (n= 11), class 2 (n= 21), class 3 (n= 24), and class 4 (n= 10).
ClaNC was then applied to the clustering solution, which further identified 540
classifier genes (Supplementary Fig. 13, Supplementary Data 13).
Differential expression analysis. The SAMR R package64 was used to identify
genes that were differentially expressed in the expression subtypes using 1000
permutations and a Q-value threshold of 0.05 (Supplementary Data 13). We then
used the DAVID annotation database65,66 to identify pathways that were enriched
for differentially expressed genes at P < 0.0001 (Supplementary Data 14).
Immunohistochemistry. FFPE tissue sections of 3-μm thickness were stained for
hematoxylin and eosin (H&E) and immunohistochemistry (IHC) was conducted
for CD56 (NCAM1), Synaptophysin (SYP), Chromogranin A (CHGA, clone DAK-
A3), TTF-1 (NKX2-1, clone 8G7G3/1), and Rb1 (RB1, clone 1F8 (ab81701; Abcam,
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Cambridge, UK) (Supplementary Data 2, Supplementary Table 1). Hematoxylin
and eosin (H&E) were scanned and can be viewed online or with the Pannoramic
Viewer software (3D Histech) as specified in Supplementary Data 2 (for further
information see “Data Availability”).
Specifically, IHC for Rb1 was performed with the Novolink max polymer
detection system (RE7280-CE, Leica Biosystems, Wetzlar, Germany) using EDTA
buffer pH 8.0 (K038, Diagnostic BioSystems, Pleasanton, USA) antigen retrieval
(4 × 5 min by microwave 700W). The primary antibody was incubated overnight at
4 °C; the secondary antibody was incubated for 30 min at room temperature. The
signal was visualized by diaminobenzidine after incubation for 5 min at room
temperature. Sections were counter-stained with hematoxylin for 5 min. The H-
score method was used for evaluating the immunostaining with Rb1 by multiplying
the intensity of the staining (0: no staining, 1: weak, 2: moderate and 3: strong
staining) with the percentage of the tumor or stroma stained. The minimum score
was 0 and the maximum was 300 (Supplementary Data 2).
Fluorescence in situ hybridization assay. Genomic rearrangements of PTK6 on
chromosome 20 were assessed through a dual-color break-apart fluorescence
in situ hybridization (FISH) assay following previous protocols67. In brief, the BAC
clone RP11-939M14 labeled centromeres with biotin (red signal) and CTD-
3228E10 labeled telomeric sites with digoxigenin (green signal). The samples were
analyzed with a 63× oil immersion objective at a fluorescence microscope (Zeiss,
Jena, Germany) equipped with appropriate filters, a charge-coupled device camera
and the FISH imaging and capturing software Metafer 4 (Metasystems, Altlus-
sheim, Germany). Two independent scientists analyzed the experiment (R.M. and
S.P.). Translocations were derived from a split of a signal pair, resulting in a single
red and green signal, single red or green signals resulting from signal loss, were
referred to as a rearrangement through deletion. In cases where cells were wild type
and displayed no rearrangements, a juxtaposed red and green signal (mostly
forming a yellow signal) was observed.
NTRK1 break-apart FISH were performed with the ZytoLight SPEC NTRK1
Dual Color Break Apart Probe (ZytoVision, Bremerhaven, Germany). According to
previous protocols68, 4 μm sections of FFPE tissue were treated with the Paraffin
pretreatment reagent kit (Vysis, Abbott Molecular), and then stained with the
probes following the instructions of the manufacturer. An NTRK1 rearrangement
was diagnosed when >15% of the nuclei showed either a split pattern with 3′ and 5′
signals separated by a distance superior to the diameter of the largest signal, or
isolated 3′ (orange) signals.
Data availability. Sequencing data and Affymetrix 6.0 SNP array data are
deposited at the European Genome-phenome Archive, which is hosted by the EBI
(EGA, http://www.ebi.ac.uk/ega/), under accession number EGAS00001000708.
Histological images of FFPE samples from LCNECs of this study are deposited as
H&E images (domain 1: https://teleslide.chu-grenoble.fr/ > acces
libre > recherche > recherche/TP/LCNEC-study > code access 1793) or as data files
compatible with the Pannoramic Viewer software (3D Histech) (domain 2: https://
uni-koeln.sciebo.de/index.php/s/xMjs4dqJpqbOVDn); an overview is provided in
Supplementary Data 2.
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